Title
Category
Credits
Event date
Cost
Achieving Value-Based Care: The Role of Oncology Clinical Pathways
  • Oncology
  • 1.00 ACPE - Pharmacists
  • 1.00 ACPE - Pharmacy Technicians
  • 1.00 AMA - Physicians
  • 1.00 ANCC - Nurses
  • 1.00 Attendance - General Attendance
  • 1.00 CCMC - General - Case Managers
$0.00
This activity will discuss best practices in cancer care, provide an overview of the current status of pathways in oncology and explore their role in helping practices to deliver value-based care.
Essentials of Oncology Management for the Health Care Team
  • Transplantation
  • 6.00 ACPE - Pharmacists
  • 6.00 ACPE - Pharmacy Technicians
  • 6.00 AMA - Physicians
  • 6.00 ANCC - Nurses
  • 6.00 APA - Psychologists
  • 6.00 Attendance - General Attendance
  • 6.00 CCMC - General - Case Managers
  • 6.00 CDR - Dietitians
  • 6.00 ASWB - Social Workers
$0.00
Throughout these activities, faculty will discuss the keys to optimize the management/benefits of individuals with cancer. Participants will hear about current topics and exciting advances in the field of oncology.
Cervical Cancer: Etiology, Diagnosis, Treatment Options and Outcomes
  • Oncology
  • 1.00 ACPE - Pharmacists
  • 1.00 ACPE - Pharmacy Technicians
  • 1.00 AMA - Physicians
  • 1.00 ANCC - Nurses
  • 1.00 APA - Psychologists
  • 1.00 Attendance - General Attendance
  • 1.00 CCMC - General - Case Managers
  • 1.00 ASWB - Social Workers
$0.00
During this educational activity, learners will become familiar with the etiology and diagnosis of cervical cancer and explore treatment options and outcomes for relapsed, recurrent and metastatic disease. Advances in current cervical cancer clinical research trials will also be addressed.
Successes, Challenges and Emerging Opportunities of CAR T-Cell Therapy
  • Disease management
  • Oncology
  • 0.75 ACPE - Pharmacists
  • 0.75 ACPE - Pharmacy Technicians
  • 0.75 AMA - Physicians
  • 0.75 ANCC - Nurses
  • 0.75 APA - Psychologists
  • 0.75 Attendance - General Attendance
  • 0.75 CCMC - General - Case Managers
  • 0.75 CDR - Dietitians
  • 0.75 ASWB - Social Workers
$0.00
This session discusses CAR T-cell therapy, its current trends, along with the challenges and costs, and what the future may hold for emerging treatment for various conditions.
Colorectal Cancer: Updates in Screening, Treatment & Research
  • Disease management
  • Oncology
  • 1.00 ACPE - Pharmacists
  • 1.00 ACPE - Pharmacy Technicians
  • 1.00 AMA - Physicians
  • 1.00 ANCC - Nurses
  • 1.00 APA - Psychologists
  • 1.00 Attendance - General Attendance
  • 1.00 CCMC - General - Case Managers
  • 1.00 CDR - Dietitians
  • 1.00 ASWB - Social Workers
$0.00
This activity discusses the current prevalence trends for CRC, new insight into risk factors, recommended screening approaches and modalities, treatment updates focused on tumor-specific molecular targets, and recent and emerging findings in CRC research and clinical trials.
The WISDOM Study: A Personalized Approach to Breast Cancer Screening
  • Disease management
  • Oncology
  • 1.00 ACPE - Pharmacists
  • 1.00 ACPE - Pharmacy Technicians
  • 1.00 ADA - CERP (Dentists/Allied Dental Staff)
  • 1.00 AMA - Physicians
  • 1.00 ANCC - Nurses
  • 1.00 APA - Psychologists
  • 1.00 Attendance - General Attendance
  • 1.00 CDR - Dietitians
  • 1.00 ASWB - Social Workers
$0.00
This activity aims to explore best practices in cancer screening and shed light on the groundbreaking WISDOM Study, which is revolutionizing our approach to screening by testing a personalized precision-medicine method based on individual risk factors for breast cancer in contrast to traditional annual mammograms. Participants will learn how this alternative approach differs from the current “one-size-fits-all” guideline-based method and discuss its potential to significantly improve the effectiveness of screening.
Active Surveillance and Management of Prostate Cancer
  • Disease management
  • Oncology
  • 1.00 AMA - Physicians
  • 1.00 ANCC - Nurses
  • 1.00 Attendance - General Attendance
$0.00
This activity will provide an overview of the natural history of early-stage prostate cancer and review current data on the benefits and drawbacks of screening. It will discuss important aspects of diagnosis and describe evidence-based strategies for detection of early-stage prostate cancer.
Cancer Control in the 21st Century: Observations on Disparities in Health
  • Disease management
  • 1.00 AMA - Physicians
  • 1.00 ANCC - Nurses
  • 1.00 Attendance - General Attendance
$0.00
The significant advancements in cancer prevention, detection and treatment seen over the past three decades have led to a general decline in cancer mortality rates; however, this decline is not consistent across all populations and demographic groups due to the persistence of disparities in access to care and optimal outcomes. This activity will provide an overview of the health disparities among segments of the population and review their impact on cancer incidence and mortality rates. It will also examine how to best promote preventive measures, incorporate culturally competent care, advocate for increased access to quality health care, and enhance patient education in order to improve health equity and provide individuals with a greater opportunity to achieve optimal health outcomes after a cancer diagnosis.
Selecting Appropriate Treatments Based on Geriatric and Fragility Assessments
  • Disease management
  • Older adults
  • Oncology
  • Transplantation
  • 0.75 ACPE - Pharmacists
  • 0.75 ACPE - Pharmacy Technicians
  • 0.75 AMA - Physicians
  • 0.75 ANCC - Nurses
  • 0.75 APA - Psychologists
  • 0.75 Attendance - General Attendance
  • 0.75 CCMC - General - Case Managers
  • 0.75 CDR - Dietitians
  • 0.75 ASWB - Social Workers
$0.00
This activity will provide an overview of geriatric and frailty assessment tools that can assist in guiding cancer- and transplant-related decision making through the risk stratification of older individuals before therapy is initiated. Data surrounding the relationship among increased age, geriatric- and frailty-assessment results, and disease outcomes will also be explored. Key considerations in how to best incorporate these sometimes time-intensive assessments into practice will be outlined, along with discussion of how interprofessional collaboration among members of the health care team in the creation of care plans can facilitate quality care.
Bladder Cancer Update: Advances in Treatment and the Role of Early Diagnosis
  • Oncology
  • 1.00 ACPE - Pharmacists
  • 1.00 ACPE - Pharmacy Technicians
  • 1.00 AMA - Physicians
  • 1.00 ANCC - Nurses
  • 1.00 APA - Psychologists
  • 1.00 Attendance - General Attendance
  • 1.00 CCMC - General - Case Managers
  • 1.00 CDR - Dietitians
  • 1.00 ASWB - Social Workers
$0.00
Bladder cancer (BC) is the tenth most common cancer worldwide, and its associated five-year survival rate declines rapidly (from 96% to 6%) as it progresses from in situ through local invasion, regional spread and finally to distal spread. Thus, early detection and timely therapeutic interventions are crucial to improve outcomes and reduce the burden of disease. Outcomes have been further improved by the integration of recently approved therapies for BC, the utilization of biomarkers to guide treatment plans and the opportunity for eligible patients with BC to enroll in clinical trials. For all treatment plans, effective communication among the health care team is crucial for providing comprehensive care for this condition. This activity will provide participants with an overview of early BC diagnosis and its impact on survival rates. It will explore recently approved therapies for BC both as standalone treatments and in combination with established therapeutic approaches. Emerging therapies and their potential benefits will be examined, and the value of biomarkers will be discussed. Participants will gain insight into treatment strategies to optimize patient outcomes in BC.